Bailiten Healthcare: The mid-term analysis of the phase III clinical trial of iza-bren for locally advanced or metastatic triple-negative breast cancer has achieved the primary endpoint.

Bailitianheng announced that its independently developed global first-in-class EGFRHER3 bispecific ADC drug iza-bren has achieved the primary endpoint in the interim analysis of a phase III clinical trial treating unresectable locally advanced or metastatic triple-negative breast cancer that has failed prior treatment with taxanes, significantly prolonging progression-free survival and overall survival. This is the third phase III clinical study where the drug has met its primary endpoint, and the first global phase III clinical study for a bispecific ADC drug to achieve dual positive results for PFS/OS in triple-negative breast cancer treatment. Currently, iza-bren has been included in the list of breakthrough therapeutic varieties for 7 indications.